Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and ...

On June 16, 2025, RemeGen Co., Ltd. ('RemeGen', stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand ...

The National Institute for Health and Care Excellence (NICE) recommended the drug not be used by the NHS due to its ...

The first patient enrolled in a planned international clinical trial has been treated at HonorHealth Research Institute with a new type of immune therapy for those with a rare muscle-weakness disease ...

Supplementary treatment with radiation and cytostatic ... No writing assistance was utilized in the production of this manuscript. Myasthenia gravis (MG) should be subgrouped into early-onset ...

As the world's first innovative biologic drug targeting both BLyS and APRIL for the treatment of myasthenia gravis (MG), Telitacicept's approval not only brings new treatment options to patients ...